Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first ...

Comparative of PD-L1 expression on live single circulating tumor cells with PD-L1 in tumor tissue assessed by immunohistochemistry in advanced NSCLC patients. This is an ASCO Meeting Abstract from the ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. Researchers evaluated 38,020 MCC cases (38% ...

Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections. CANTON, Mass.–(BUSINESS WIRE)–December 10, 2024– Orthogon Therapeutics, a developer of novel antiviral ...

Merkel cell polyomavirus is one of seven viruses known to cause cancer in humans. Infection with this virus is asymptomatic, but, rarely, it can lead to the development of Merkel cell carcinoma (MCC), ...

Most often we think about cancer as developing from cells that acquire cancer-driving mutations, but there’s a subset of cancers driven by another culprit: viruses. To date, “seven human viruses have ...

Please provide your email address to receive an email when new articles are posted on . 65.1% and 63.8% of Merkel cell carcinoma cases were attributed to ambient ultraviolet radiation exposure and ...

BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that the clinical strategy ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing ...